相关实验视频

Updated: Jul 11, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

作为急性髓性白血病的治疗方法,LAIR-1激动症

Rustin R Lovewell¹, Junshik Hong^2,3,4, Subhadip Kundu¹

¹NextCure Inc., Beltsville, Maryland, USA.

The Journal of clinical investigation

|November 15, 2023

概括

一种针对免疫受体LAIR-1的新型抗体在急性髓性白血病 (AML) 模型中有效消除白血病干细胞 (LSC). 这种方法显示出作为一种新的治疗策略的希望,有可能增强目前的治疗方法.

科学领域:

免疫学免疫学免疫学
血液学血液学血液学
在瘤学瘤学.

背景情况:

白血病干细胞 (LSC) 是急性髓性白血病 (AML) 的关键驱动因素,并构成重大治疗挑战.
免疫受体LAIR-1调节LSC的存活率,但其在AML的治疗潜力在很大程度上尚未被探索.

研究的目的:

调查针对LAIR-1途径在AML中的治疗潜力.
开发和评估一个LAIR-1主动性抗体用于LSC根除.

主要方法:

开发一个LAIR-1主动性抗体 (NC525).
在体外评估NC525的LSC和健康的造血干细胞.
在细胞和患者衍生的AML异种移植模型中NC525的体内评估.
分析LAIR-1激动诱导信号通路和与标准疗法的协同作用.

主要成果:

NC525在LSC中选择性诱导细胞死亡,在体外省略健康的造血干细胞.
在体内,NC525在根除LSC和AML爆发方面表现出有效性.
在白血病细胞中,LAIR-1激素激活了独特的亡途径,由原增强.
NC525显著增强了阿扎西提丁和venetoclax的活性.

结论:

用NC525等激进抗体向LAIR-1代表了AML的一种有前途的治疗策略.
LAIR-1激动症为消除LSC提供了一种新的方法,并可能与现有的AML治疗产生协同作用.

关键词:

在白血病中,白血病.在瘤学瘤学.

更多相关视频

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...